Haruo Naito, Eisai CEO (The Yomiuri Shimbun via AP Images)
May 15, 2025 03:25 PM EDT
Pharma

Ei­sai says Leqem­bi is head­ed for 'de­mand ex­pan­sion phase' in US

Nicole DeFeudis

Editor

Ei­sai ex­ec­u­tives said on Thurs­day that Leqem­bi sales and ship­ments in the US are show­ing “steady growth and ex­pan­sion,” just a cou­ple months af­ter the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

New CBER chief Prasad is ready­ing 'mas­sive frame­work' around vac­cines, Makary says

Bris­tol My­ers CEO says Amer­i­ca’s bio­phar­ma pole po­si­tion is not guar­an­teed

Ex­clu­sive: Drug com­pounder Em­pow­er was built on risky short­cuts, ex-em­ploy­ees and in­spec­tions al­lege

Eli Lil­ly turns to South Ko­re­an RNA edit­ing biotech for hear­ing loss in deal worth $1.3B

Bio­haven stock sinks on three-month de­lay for neu­ro drug's FDA ap­proval de­ci­sion

A service from the Financial Times